EL7.AI
Mergers & AcquisitionsMediumUpdated•Originally published 13 September 2026•Updated 13 September 2026•
1 min read

GE HealthCare in Talks to Acquire Sofie Biosciences for $1 Billion

Handshake between GE HealthCare and Sophia Genetics logos over a $1 billion sign and medical equipment.

Key Facts

1GE HealthCare Technologies is in talks to acquire radiopharmaceutical developer Sofie Biosciences.
2The potential deal is expected to be valued at approximately $1 billion.

In a move reflecting strategic expansion within the specialized healthcare sector, GE HealthCare Technologies is in talks to acquire Sofie Biosciences. According to reports, this potential deal aims to bolster the company's capabilities in radiopharmaceuticals and chemicals used for cancer scans. The acquisition is expected to be valued at approximately $1 billion, marking a significant strategic step following its spin-off from General Electric.

This news comes as the healthcare technology sector seeks to integrate advanced diagnostic solutions to increase market share. Based on the available data, the acquisition of Sofie Biosciences specifically focuses on radiopharmaceutical development, a rapidly growing field. Per market data, the estimated $1 billion valuation reflects confidence in the target company's technical assets and its ability to integrate with GEHC's existing infrastructure.

Looking at equity performance, the GEHC share price stood at $63.93 (close September 11, 2026), with a daily high of $65.4 and a low of $63.22. Traders are currently monitoring for official announcements to confirm deal specifics, while the upcoming economic calendar shows no direct sector-related catalysts over the next seven days, leaving acquisition developments as the primary driver for the stock.